Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Laia Boronat
Observed names:
L. Boronat,
L. Boronat Ruiz
Institution:
Hospital Universitari Germans Trias i Pujol
Observed institutions:
Universitat Autònoma de Barcelona,
Hospital de Sant Pau,
Hospital Universitario Nuestra Señora de Candelaria,
Institut Català d'Oncologia,
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol,
Hospital Universitari Germans Trias i Pujol
show all 6
ORCID:
0009-0003-7514-3110
Observed ORCID:
0009-0003-7514-3110
OpenAlex ID:
A5089862433
Differential Transcriptome Profile of Peripheral White Cells to Identify Biomarkers Involved in Oxaliplatin Induced Neuropathy
2014
·
Manuel Morales
, Julio Ávila
, et al.
·
Journal of Personalized Medicine
·
16
PDF
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
2024
·
N. Martínez-Jañez
, M. Bellet Ezquerra
, et al.
·
Breast Cancer Research and Treatment
·
12
PDF
Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy
2024
·
Iris Teruel
, Eva Castellà
, et al.
·
International Journal of Molecular Sciences
·
8
PDF
Circulating miRNA Expression Is Inversely Correlated with Tumor Tissue or Sentinel Lymph Nodes in Estrogen Receptor-Positive Early Breast Cancer Patients
2023
·
Daniel Escuin
, Laura López-Vilaró
, et al.
·
International Journal of Molecular Sciences
·
6
PDF
234P Real-world treatment patterns and outcomes of patients receiving palbociclib plus endocrine therapy in Spain: Subgroup analysis based on age, sites and number of metastatic locations, menopausal status and dose received from PALBOSPAIN study
2023
·
F. Moreno Anton
, M. Bellet-Ezquerra
, et al.
·
ESMO Open
·
5
PDF
Abstract P4-01-28: PALBOSPAIN: OBSERVATIONAL ANALYSIS OF FIRST-LINE THERAPY WITH PALBOCICLIB IN PATIENTS WITH HR+/HER2- METASTATIC BREAST CANCER (MBC) IN REAL-LIFE CONDITIONS
2023
·
Noelia Martínez-Jáñez
, Meritxell Bellet Ezquerra
, et al.
·
Cancer Research
·
5
Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer
2024
·
Anna Pous
, Adrià Bernat-Peguera
, et al.
·
Therapeutic Advances in Medical Oncology
·
4
Immune‐based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer
2025
·
Eudald Felip
, Edurne Garcia‐Vidal
, et al.
·
Clinical and Translational Medicine
·
2
PDF
Abstract PO1-16-08: Real-World Outcomes of Patients Receiving First-line Palbociclib Plus Endocrine Therapy in Spain: Subgroup Analysis Based on Tumor Grade, Progesterone Receptor, Ki-67 and Histological Subtype from PALBOSPAIN Study
2024
·
Fernando Moreno
, Meritxell Bellet- Ezquerra
, et al.
·
Cancer Research
·
1
Abstract PS2-10-27: Unmasking Sampling Artefacts in Early Breast Cancer: Molecular Shifts Between Diagnostic and Surgical Specimens in the Absence of Therapy
2026
·
M. A. Bergamino Sirvén
, A. Pous
, et al.
·
Clinical Cancer Research
Abstract P2-03-28: Immune-based gene expression signature determines clinical efficacy of CDK4/6i in HR+HER2- breast cancer
2025
·
Eudald Felip
, Sara Cabrero-De las Heras
, et al.
·
Clinical Cancer Research
283P Incidence of male breast cancer in genetically high-risk patients
2025
·
G. Zatta Cobos
, I. Teruel-Garcia
, et al.
·
ESMO Open
PDF
75P Defining an immune signature as a CDK4/6i efficacy predictor in HR+HER2- breast cancer
2025
·
E. Garcia-Vidal
, E. Felip Falgas
, et al.
·
ESMO Open
PDF
360P Identification of circulating immune factors as predictive biomarkers of CDK4/6i treatment efficacy in advanced breast cancer
2024
·
S. Cabrero-de las Heras
, E. Felip Falgas
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
14
Citation count:
59
H-index:
5
I10-index:
2
Year
Topic
Type